Table 1.

Summary of clinical trials using ATCVs for the management of breast cancer.

Phase	ATCV Composition	Stage	Significant Clinical Findings	Ref.
I	Irradiated autologous tumor cells expressing GM-CSF	IV	Study in progress	[36]
I/II	Irradiated autologous tumor cells expressing GM-CSF	II-III	Study in progress	[37]
*	Irradiated autologous tumor cell infected with Newcastle disease virus	I-IV	96% 4-year survival for breast cancer patients receiving high quality vaccine vs. 68% for low quality vaccine	[34]
II	Autologous and allogeneic (MCF-7) tumor cells with CA 15-3, CEA, CA 125 proteins and IL-2 and GM-CSF	I-IV	2/16 patients with metastatic breast cancer had a partial response; 7/16 had stable disease for 6 to 55 months	[35]
*	Autologous and allogeneic (MCF-7) tumor cells with CA 15-3, CEA, CA 125 proteins and IL-2 and GM-CSF	I-III	89% 10-year disease-specific survival of patients vaccinated compared to 59% for unvaccinated historical controls	[27]

^*Phase could not be determined.